AstraZeneca PLC (NASDAQ:AZN) Shares Acquired by XML Financial LLC

XML Financial LLC increased its position in AstraZeneca PLC (NASDAQ:AZN) by 11.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,398 shares of the company’s stock after purchasing an additional 650 shares during the quarter. XML Financial LLC’s holdings in AstraZeneca were worth $419,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in AZN. 1832 Asset Management L.P. increased its holdings in AstraZeneca by 7.0% during the 2nd quarter. 1832 Asset Management L.P. now owns 65,772 shares of the company’s stock worth $5,130,000 after purchasing an additional 4,280 shares during the last quarter. Evergreen Capital Management LLC increased its stake in shares of AstraZeneca by 6.7% in the second quarter. Evergreen Capital Management LLC now owns 20,231 shares of the company’s stock worth $1,578,000 after buying an additional 1,270 shares during the last quarter. Point72 Asset Management L.P. increased its stake in shares of AstraZeneca by 166.2% in the second quarter. Point72 Asset Management L.P. now owns 498,950 shares of the company’s stock worth $38,913,000 after buying an additional 311,550 shares during the last quarter. Fred Alger Management LLC raised its holdings in AstraZeneca by 338.0% in the second quarter. Fred Alger Management LLC now owns 264,373 shares of the company’s stock valued at $20,618,000 after acquiring an additional 204,009 shares in the last quarter. Finally, Point72 Hong Kong Ltd bought a new position in AstraZeneca during the 2nd quarter valued at $518,000. 20.35% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently weighed in on AZN. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Price Performance

AZN opened at $68.20 on Thursday. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The company’s 50-day moving average price is $66.20 and its 200 day moving average price is $74.32. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68. The firm has a market cap of $211.49 billion, a price-to-earnings ratio of 32.63, a price-to-earnings-growth ratio of 1.13 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The business had revenue of $13.57 billion for the quarter, compared to analysts’ expectations of $13.08 billion. During the same period in the prior year, the firm earned $0.87 EPS. The business’s quarterly revenue was up 18.0% on a year-over-year basis. As a group, sell-side analysts expect that AstraZeneca PLC will post 4.12 earnings per share for the current year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.